Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has announced that the Canadian Federal Court has issued judgment in a lawsuit in which Johnson & Johnson had accused the company's NIR stent of infringing two Johnson & Johnson Palmaz patents.
Subscribe to our email newsletter
The Court dismissed Johnson & Johnson’s lawsuit, found that the company’s NIR stent did not infringe one patent of Johnson & Johnson, and found that the other Johnson & Johnson patent was invalid.
Johnson & Johnson recently filed a second lawsuit in Canada in which the company’s Express and Taxus Express stents are accused of infringing these same two patents.
Paul LaViolette, COO of Boston Scientific, said: “The ruling affirms our position that our products do not infringe these patents. We also believe our Express and Taxus Express coronary stents do not infringe as alleged by Johnson & Johnson and are hopeful the Court will reach the same conclusion.”